Literature DB >> 9578834

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors.

S J Advani1, G S Sibley, P Y Song, D E Hallahan, Y Kataoka, B Roizman, R R Weichselbaum.   

Abstract

Human U-87 malignant glioma xenografts in mice were exposed to ionizing radiation, inoculated with a herpes simplex virus 1 mutant R3616 lacking both copies of the gamma 34.5 gene, or received both virus and radiation. Dual treatment caused a significantly greater reduction in volume or total regression of tumors than either radiation or infection alone. The significantly enhanced oncolytic effects of the combined treatment correlate with two-to five-fold enhanced replication in irradiated tumor cells than in tumors receiving virus only. In addition, in situ hybridization with viral DNA probes showed that infected tumor cells were the dominant landscape of irradiated tumors and much less apparent in the nonirradiated tumors administered this virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578834     DOI: 10.1038/sj.gt.3300546

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  35 in total

Review 1.  Conditionally replicating herpes vectors for cancer therapy.

Authors:  R L Martuza
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 4.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 5.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 6.  Intelligent design: combination therapy with oncolytic viruses.

Authors:  Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2009-12-22       Impact factor: 11.454

7.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.

Authors:  Alicia M Waters; James M Johnston; Alyssa T Reddy; John Fiveash; Avi Madan-Swain; Kara Kachurak; Asim K Bag; G Yancey Gillespie; James M Markert; Gregory K Friedman
Journal:  Hum Gene Ther Clin Dev       Date:  2017-03       Impact factor: 5.032

8.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors:  Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

10.  Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.

Authors:  Karsten Geletneky; Andreas D Hartkopf; Robert Krempien; Jean Rommelaere; Joerg R Schlehofer
Journal:  J Biomed Biotechnol       Date:  2010-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.